Septerna
SEPN
36.00
+0.33
+0.93%
Septerna
US · SEPN
#2886 by market cap
Listed 2024
36.00
+0.33
+0.93%
Live - 5344 symbols - heartbeat 418s ago
· 2026-10-07 19:54
After-hours
36.00
0.00%
- Market cap
- 1.68B
- P/E (TTM)i
- -67.92
- P/Bi
- 4.35
- EPSi
- -1.10
- Div yieldi
- 0.00%
- 52W posi
- 55%
Reader sentiment
Are you bullish or bearish on SEPN?
Anonymous reader poll. Unscientific, not investment advice.
About Septerna
Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.
- Founded
- 2019
- CEO
- Dr. Jeffrey T. Finer, M.D.,PhD
- Employees
- 130
- Headquarters
- South San Francisco, California, United States of America
- Fiscal year end
- 12-31
- Website
- septerna.com
Company profile
- Exchange
- US
- Symbol
- SEPN
- Market-cap rank
- #2886
- Listing date
- 2024-10-25
- Market cap
- 1.68B
- Float cap
- 824.27M
- Shares out
- 46.68M
- Float shares
- 22.90M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.